SNK-225

SNK-225 is a preclinical-stage therapeutic candidate being developed by Synakis for the treatment of glaucoma. It consists of a small molecule prodrug formulated within a proprietary, injectable, and biodegradable hydrogel delivery system. The platform is designed to provide sustained release of the medication into the eye via affinity-controlled mechanisms, potentially reducing the need for daily eye drops and improving patient compliance. By maintaining a controlled release profile over several months, SNK-225 aims to provide consistent intraocular pressure (IOP) reduction while minimizing the systemic side effects and adherence issues associated with traditional topical therapies.